A pilot pharmacologic biomarker study of busulfan and fludarabine in hematopoietic cell transplant recipients

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 1, 2012, Pages 263-272

  McCune, Jeannine S ^a,c   Woodahl, Erica L ^a,c,d   Furlong, Terry ^c   Storer, Barry ^c   Wang, Joanne ^a,c   Heimfeld, Shelly ^c   Deeg, H Joachim ^b,c   O'Donnell, Paul V ^b,c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d UNIVERSITY OF MONTANA   (United States)

Author keywords

Biomarkers; Busulfan; Fludarabine; Hematopoietic cell transplant; Pharmacokinetics; Therapeutic drug monitoring

Indexed keywords

BUSULFAN; FLUDARABINE; METHOTREXATE; PHARMACOLOGICAL BIOMARKER; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER RELAPSE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG ACCUMULATION; DRUG SENSITIVITY; FEMALE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LYMPHOCYTE SUBPOPULATION; MALE; MORTALITY; OVERALL SURVIVAL; PILOT STUDY; PRIORITY JOURNAL; STEADY STATE; STEROID THERAPY;

ADULT; AGED; ANTILYMPHOCYTE SERUM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; BIOMARKERS, PHARMACOLOGICAL; BUSULFAN; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; SURVIVAL RATE; VIDARABINE PHOSPHATE;

EID: 84856750122     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1736-3     Document Type: Article

References (33)

1. JS McCune A Batchelder HJ Deeg T Gooley S Cole B Phillips HG Schoch GB McDonald 2007 Cyclophosphamide following targeted oral busulfan as conditioning for hematopoietic cell transplantation: pharmacokinetics, liver toxicity, and mortality Biol Blood Marrow Transplant 13 7 853 862 17580264 10.1016/j.bbmt.2007.03.012 1:CAS:528:DC%2BD2sXosVKmurw%3D (Pubitemid 46902444)
2. M Bornhauser B Storer JT Slattery FR Appelbaum HJ Deeg J Hansen PJ Martin GB McDonald WG Nichols J Radich A Woolfrey A Jenke E Schleyer C Thiede G Ehninger C Anasetti 2003 Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells Blood 102 3 820 826 12676781 10.1182/blood-2002-11-3567 (Pubitemid 36917770)
3. JA Russell AR Turner L Larratt A Chaudhry D Morris C Brown D Quinlan D Stewart 2007 Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis Biol Blood Marrow Transplant 13 3 299 306 10.1016/j.bbmt.2006.10.017 17317583 10.1016/j.bbmt.2006.10.017 1:CAS:528:DC%2BD2sXjvFKqu7g%3D
4. Andersson BS, de Lima M, Thall PF, Wang X, Couriel D, Korbling M, Roberson S, Giralt S, Pierre B, Russell JA, Shpall EJ, Jones RB, Champlin RE (2008) Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. Biol Blood Marrow Transplant 14(6):672-684 (Pubitemid 351664062)
5. CN Bredeson MJ Zhang MA Agovi A Bacigalupo NJ Bahlis K Ballen C Brown MA Chaudhry MM Horowitz S Kurian D Quinlan CE Muehlenbien JA Russell L Savoie JD Rizzo DA Stewart 2008 Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide Biol Blood Marrow Transplant 14 9 993 1003 10.1016/j.bbmt.2008.06.009 18721762 10.1016/j.bbmt.2008.06.009 1:CAS:528:DC%2BD1cXhtFemurvK
6. JS McCune LA Holmberg 2009 Busulfan in hematopoietic stem cell transplant setting Expert Opin Drug Metab Toxicol 5 8 957 969 10.1517/17425250903107764 19611402 10.1517/17425250903107764 1:CAS:528:DC%2BD1MXovVCjurc%3D
7. Geddes M, Kangarloo SB, Naveed F, Quinlan D, Chaudhry MA, Stewart D, Savoie ML, Bahlis NJ, Brown C, Storek J, Andersson BS, Russell JA (2008) High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen. Biol Blood Marrow Transplant 14 (2):220-228
8. SO Ciurea BS Andersson 2009 Busulfan in hematopoietic stem cell transplantation Biol Blood Marrow Transplant 15 5 523 536 10.1016/j.bbmt.2008. 12.489 19361744 10.1016/j.bbmt.2008.12.489 1:CAS:528:DC%2BD1MXlsFOhu74%3D
9. L Danhauser W Plunkett J Liliemark V Gandhi S Iacoboni M Keating 1987 Comparison between the plasma and intracellular pharmacology of 1-beta-d-arabinofuranosylcytosine and 9-beta-d-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemia Leukemia 1 9 638 643 3478543 1:STN:280:DyaL1c%2FjslGnuw%3D%3D (Pubitemid 17154182)
10. V Gandhi W Plunkett 2002 Cellular and clinical pharmacology of fludarabine Clin Pharmacokinet 41 2 93 103 11888330 10.2165/00003088-200241020- 00002 1:CAS:528:DC%2BD38XjtFakt7s%3D (Pubitemid 34264036)
11. T Robak E Lech-Maranda A Korycka E Robak 2006 Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity Current Med Chem 13 26 3165 3189 10.2174/092986706778742918 1:CAS:528:DC%2BD28XhtVClurjN (Pubitemid 44680862)
12. SA Johnson 2000 Clinical pharmacokinetics of nucleoside analogues: focus on haematological malignancies Clin Pharmacokinet 39 1 5 26 10926348 10.2165/00003088-200039010-00002 1:CAS:528:DC%2BD3cXlvVSjurw%3D (Pubitemid 30468202)
13. Woodahl EL, Wang J, Heimfeld S, Sandmaier BM, O'Donnell PV, Phillips B, Risler L, Blough DK, McCune JS (2009) A novel phenotypic method to determine fludarabine triphosphate accumulation in T-lymphocytes from hematopoietic cell transplantation patients. Cancer Chemother Pharmacol 63(3):391-401
14. EW Petersdorf C Anasetti PJ Martin T Gooley J Radich M Malkki A Woolfrey A Smith E Mickelson JA Hansen 2004 Limits of HLA mismatching in unrelated hematopoietic cell transplantation Blood 104 9 2976 2980 15251989 10.1182/blood-2004-04-1674 1:CAS:528:DC%2BD2cXpslKisrk%3D (Pubitemid 39434990)
15. JA Russell HT Tran D Quinlan A Chaudhry P Duggan C Brown D Stewart JD Ruether D Morris S Glick E Gyonyor BS Andersson 2002 Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes Biol Blood Marrow Transplant 8 9 468 476 12374451 10.1053/bbmt.2002.v8.pm12374451 1:CAS:528:DC%2BD38Xot1Ggsrc%3D (Pubitemid 35174820)
16. Salinger DH, Vicini P, Blough DK, O'Donnell PV, Pawlikowski MA, McCune JS (2010) Development of a population pharmacokinetics-based sampling schedule to target daily intravenous busulfan for outpatient clinic administration. J Clin Pharmacol. doi: 10.1177/0091270009357430
17. D Przepiorka D Weisdorf P Martin HG Klingemann P Beatty J Hows ED Thomas 1995 1994 consensus conference on acute GVHD grading Bone Marrow Transplant 15 6 825 828 7581076 1:STN:280:DyaK28%2Fot1Ojtw%3D%3D
18. SJ Lee G Vogelsang ME Flowers 2003 Chronic graft-versus-host disease Biol Blood Marrow Transplant 9 4 215 233 10.1053/bbmt.2003.50026 12720215 10.1053/bbmt.2003.50026 1:CAS:528:DC%2BD3sXltFaqt7s%3D (Pubitemid 40045609)
19. HJ Deeg 2007 How I treat refractory acute GVHD Blood 109 10 4119 4126 10.1182/blood-2006-12-041889 17234737 10.1182/blood-2006-12-041889 1:CAS:528:DC%2BD2sXls1anurg%3D (Pubitemid 46743372)
20. M Bonin S Pursche T Bergeman T Leopold T Illmer G Ehninger E Schleyer M Bornhauser 2007 F-ara-A pharmacokinetics during reduced-intensity conditioning therapy with fludarabine and busulfan Bone Marrow Transplant 39 4 201 206 17211431 10.1038/sj.bmt.1705565 1:CAS:528:DC%2BD2sXhsV2isLY%3D
21. GB Segel GR Cokelet MA Lichtman 1981 The measurement of lymphocyte volume: importance of reference particle deformability and counting solution tonicity Blood 57 5 894 899 7214019 1:STN:280:DyaL3M7mtFGhtQ%3D%3D (Pubitemid 11096481)
22. JT Slattery LJ Risler 1998 Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation Ther Drug Monit 20 5 543 549 9780133 10.1097/00007691-199810000-00017 1:CAS:528:DyaK1cXmvFKhsr0%3D (Pubitemid 28463447)
23. Stem Cell Trialists' Collaborative Group (2005) Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol 23(22):5074-5087. doi: 10.1200/JCO.2005.09.020 (Pubitemid 46224015)
24. PJ Martin GB McDonald JE Sanders C Anasetti FR Appelbaum HJ Deeg RA Nash EW Petersdorf JA Hansen R Storb 2004 Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation Biol Blood Marrow Transplant 10 5 320 327 15111931 10.1016/j.bbmt.2003.12.304 (Pubitemid 38519570)
25. DM Hockenbery S Cruickshank TC Rodell T Gooley F Schuening S Rowley D David M Brunvand B Berryman S Abhyankar M Bouvier GB McDonald 2007 A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease Blood 109 10 4557 4563 17244684 10.1182/blood-2006-05-021139 1:CAS:528: DC%2BD2sXls1amtro%3D (Pubitemid 46743427)
26. HJ Kolb R Storb PL Weiden HD Ochs H Kolb TC Graham GL Floersheim ED Thomas 1974 Immunologic, toxicologic and marrow transplantation studies in dogs given dimethyl myleran Biomedicine 20 5 341 351 4615750 1:CAS:528: DyaE2MXptlamtg%3D%3D
27. GW Santos PJ Tutschka 1974 Marrow transplantation in the busulfan-treated rat: preclinical model of aplastic anemia J Natl Cancer Inst 53 6 1781 1785 4612168 1:STN:280:DyaE2M%2Fmt1Sntg%3D%3D
28. Yeh RF, Pawlikowski MA, Blough DK, McDonald GB, O'Donnell PV, Rezvani A, Deeg HJ, McCune JS (2011) Accurate targeting of daily intravenous busulfan with 8-hour blood sampling in hospitalized adult hematopoietic cell transplant recipients. Biol Blood Marrow Transplant. doi: 10.1016/j.bbmt.2011.06.013
29. JT Slattery JE Sanders CD Buckner RL Schaffer KW Lambert FP Langer C Anasetti WI Bensinger LD Fisher FR Appelbaum, et al. 1995 Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics Bone Marrow Transplant 16 1 31 42 7581127 1:STN:280: DyaK28%2FotVyjsQ%3D%3D
30. GB McDonald JT Slattery ME Bouvier S Ren AL Batchelder TF Kalhorn HG Schoch C Anasetti T Gooley 2003 Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation Blood 101 5 2043 2048 12406916 10.1182/blood-2002-06-1860 1:CAS:528:DC%2BD3sXhslCrtbc%3D (Pubitemid 36237612)
31. JS McCune A Batchelder KA Guthrie R Witherspoon FR Appelbaum B Phillips P Vicini DH Salinger GB McDonald 2009 Personalized dosing of cyclophosphamide in the total body irradiation-cyclophosphamide conditioning regimen: a phase II trial in patients with hematologic malignancy Clin Pharmacol Ther 85 6 615 622 19295506 10.1038/clpt.2009.27 1:CAS:528:DC%2BD1MXmtVOgtbY%3D
32. Jacobson PA, Rogosheske J, Green K, Brunstein C, Barker J, Miller J, Wagner J, McGlave P, Tan Y, Weisdorf D (2005) Fludarabine Pharmacokinetics in nonmyeloablative hematopoietic cell transplantation (HCT): association with engraftment and neurotoxicity. Blood 106. Abstract #3673
33. DH Salinger DK Blough P Vicini C Anasetti PV O'Donnell BM Sandmaier JS McCune 2009 A limited sampling schedule to estimate individual pharmacokinetic parameters of fludarabine in hematopoietic cell transplant patients Clin Cancer Res 15 16 5280 5287 10.1158/1078-0432.CCR-09-0427 19671874 10.1158/1078-0432. CCR-09-0427 1:CAS:528:DC%2BD1MXpvFeitb4%3D